ATE307885T1 - Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren - Google Patents

Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren

Info

Publication number
ATE307885T1
ATE307885T1 AT96921279T AT96921279T ATE307885T1 AT E307885 T1 ATE307885 T1 AT E307885T1 AT 96921279 T AT96921279 T AT 96921279T AT 96921279 T AT96921279 T AT 96921279T AT E307885 T1 ATE307885 T1 AT E307885T1
Authority
AT
Austria
Prior art keywords
cloned
binding protein
macrophage activation
factors derived
activation factors
Prior art date
Application number
AT96921279T
Other languages
English (en)
Inventor
Nobuto Yamamoto
Original Assignee
Nobuto Yamamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/478,121 external-priority patent/US5620846A/en
Application filed by Nobuto Yamamoto filed Critical Nobuto Yamamoto
Application granted granted Critical
Publication of ATE307885T1 publication Critical patent/ATE307885T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
AT96921279T 1995-06-07 1996-06-05 Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren ATE307885T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/478,121 US5620846A (en) 1995-06-07 1995-06-07 Diagnostic and prognostic indices for cancer and aids
US08/618,485 US6410269B1 (en) 1995-06-07 1996-03-19 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
PCT/US1996/008867 WO1996040903A1 (en) 1995-06-07 1996-06-05 Macrophage activating factors derived from cloned vitamin d binding protein

Publications (1)

Publication Number Publication Date
ATE307885T1 true ATE307885T1 (de) 2005-11-15

Family

ID=27045792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921279T ATE307885T1 (de) 1995-06-07 1996-06-05 Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren

Country Status (12)

Country Link
US (3) US6410269B1 (de)
EP (3) EP1443112A3 (de)
JP (1) JPH11511962A (de)
CN (2) CN1174097C (de)
AT (1) ATE307885T1 (de)
AU (1) AU6253596A (de)
BR (1) BR9609072A (de)
CA (1) CA2223940A1 (de)
DE (2) DE69635346D1 (de)
ES (1) ES2252756T3 (de)
NO (1) NO323155B1 (de)
WO (1) WO1996040903A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985545A (en) * 1996-03-19 1999-11-16 Yamamoto; Nobuto Diagnostic and prognostic ELISA assays of serum α-N-acetylgalactosaminidase for AIDS
AU6137801A (en) * 2000-05-09 2001-11-20 Childrens Medical Center Method and composition for the treatment of angiogenesis
US20050009120A1 (en) * 2000-09-07 2005-01-13 The Brigham And Women's Hospital, Inc. Methods of detecting ovarian cancer based on osteopontin
US6846642B2 (en) * 2000-09-07 2005-01-25 The Brigham And Women's Hospital, Inc. Methods of detecting cancer based on prostasin
AU2002246849A1 (en) * 2000-11-09 2002-08-06 Northeastern Ohio Universities College Of Medicine Agents and methods for promoting bone growth
WO2002075314A2 (en) * 2000-11-30 2002-09-26 Matritech, Inc. Detection and treatment of prostate cancer
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7288383B2 (en) * 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer
US8034773B2 (en) 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2006063028A2 (en) * 2004-12-07 2006-06-15 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US8460697B2 (en) 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7838497B2 (en) 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
US8496942B2 (en) 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US7811995B2 (en) 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
AU2010289901A1 (en) * 2009-08-22 2012-03-15 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation
JP5860401B2 (ja) 2010-09-03 2016-02-16 森田薬品工業株式会社 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
CA2832487A1 (en) 2011-04-07 2012-10-11 Efranat Ltd. Macrophage activating factor for pharmaceutical compositions
EP2561879A1 (de) 2011-08-23 2013-02-27 Protea Biopharma N.V. Makrophagenaktivierungsfaktor zur Verwendung bei der Behandlung des chronischen Ermüdungssyndroms sowie Erkrankungen und Störungen im Zusammenhang mit dem chronischen Ermüdungssyndrom
EP2819749A4 (de) * 2012-03-01 2016-03-02 Univ Columbia Biomarker für autismus und verwendungen davon
EP2687264A1 (de) 2012-07-17 2014-01-22 Protea Biopharma N.V. Macrophagen Activierender Faktor zur Behandlung der Endometriose
KR20150107738A (ko) * 2013-01-18 2015-09-23 엘리스 클라인 암의 면역 프로그래밍 및 치료를 위한 선택적 글라이코시다제 섭생
AU2014279627A1 (en) * 2013-06-09 2015-12-03 Efranat Ltd. Compositions comprising Gc- macrophage activating factor and uses thereof
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
JP6718561B2 (ja) * 2017-12-15 2020-07-08 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法
AU2021398261A1 (en) 2020-12-08 2023-07-06 Saisei Pharma Co., Ltd. Macrophage activator
CN118325844B (zh) * 2023-09-07 2025-01-03 武汉奥科博泰生物科技有限公司 识别N-乙酰-β-D-氨基葡萄糖苷酶的单克隆抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5177001A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene

Also Published As

Publication number Publication date
NO975771L (no) 1998-01-30
CA2223940A1 (en) 1996-12-19
US6410269B1 (en) 2002-06-25
JPH11511962A (ja) 1999-10-19
EP0837932A1 (de) 1998-04-29
AU6253596A (en) 1996-12-30
EP1340815A3 (de) 2003-09-17
US20020055140A1 (en) 2002-05-09
DE69635346T4 (de) 2007-11-08
CN1174097C (zh) 2004-11-03
NO323155B1 (no) 2007-01-08
EP1443112A3 (de) 2004-11-03
EP0837932B1 (de) 2005-10-26
EP1443112A2 (de) 2004-08-04
EP1340815A2 (de) 2003-09-03
ES2252756T3 (es) 2006-05-16
DE69635346T2 (de) 2006-07-27
DE69635346D1 (de) 2005-12-01
NO975771D0 (no) 1997-12-08
US5712104A (en) 1998-01-27
CN1510147A (zh) 2004-07-07
WO1996040903A1 (en) 1996-12-19
EP0837932A4 (de) 2001-02-28
CN1191567A (zh) 1998-08-26
BR9609072A (pt) 2000-10-24

Similar Documents

Publication Publication Date Title
ATE307885T1 (de) Von kloniertem, vitamin-d bindenden protein abgeleitete makrophagen-aktivierende faktoren
AU3503795A (en) Synthesis of proteins by native chemical ligation calicheamicin mimics
EP1712623A3 (de) Selektion von Proteinen unter Verwendung von RNA-protein-fusionen
HU9600692D0 (en) Human metabotropic glutamate receptor subtypes (hmr4, hmr6, hmr7) and related dna compounds
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
DK0866876T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner i E.coli ved hjælp af fermentering i høje celletætheder
DE69613754D1 (de) Zusammensetzung und Verfahren zur Papierleimung
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
EP0754229A1 (de) Afamin: ein menschliches serum albumin ähnliches protein
ATE242808T1 (de) Cytoplasmatische expression von antikörpern, antikörperfragmenten und antikörperfragment- fusionsmolekülen in e. coli
NO982715D0 (no) Endotel celle-proliferasjonsinhibitor og fremgangsmÕte for anvendelse
AU5759399A (en) Peptide derivative
ATE285474T1 (de) Haemophilus adhäsionsproteinen
DK0781341T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner, plasmider og modificerede celler
AU7423391A (en) Dna constructs for the expression of proteins in the mammary gland of transgenetic mammals
EP0635016A4 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden.
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
Kikkawa et al. Identification of laminin α5 short arm peptides active for endothelial cell attachment and tube formation
CA2199403A1 (en) Novel PKA-Binding Proteins and Uses Thereof
AU5173996A (en) Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels
WO1998019160A3 (de) VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU
CA2199843A1 (en) Novel PKA-Binding Proteins and Uses Thereof
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
AU7390891A (en) Anti-oncostatin m monoclonal antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties